Merck (MRK) Non-Current Assets (2009 - 2026)
Merck (MRK) reported Non-Current Assets of $125.0 million for Q1 2026, down 99.84% year-over-year from $79.6 billion in Q1 2025, and little changed on a QoQ basis from $125.0 million in Q4 2025.
Merck (MRK) has 18 years of Non-Current Assets data on file, last reported at $125.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 99.84% year-over-year to $125.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.0 million (down 99.96% YoY) and the FY2025 annual result came in at $125.0 million, changed N/A from the prior year.
- Non-Current Assets was little changed at $125.0 million in Q1 2026 per MRK's latest filing, from $125.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $82.0 billion in Q3 2025 and bottomed at $125.0 million in Q4 2025.
- The 5-year median for Non-Current Assets is $74.5 billion (2023), against an average of $66.5 billion.
- The widest annual swing landed in 2022, when Non-Current Assets gained 20.89%; it then sank 99.84% in 2026.
- Tracing MRK's Non-Current Assets over 5 years: stood at $73.4 billion in 2022, then advanced by 1.46% to $74.5 billion in 2023, then climbed by 3.58% to $77.2 billion in 2024, then tumbled by 99.84% to $125.0 million in 2025, then changed by 0.0% to $125.0 million in 2026.
- Per Business Quant, the three latest MRK Non-Current Assets figures stand at $125.0 million (Q1 2026), $125.0 million (Q4 2025), and $82.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 58.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.00 Mn |
| Dec 31, 2025 | 125.00 Mn |
| Sep 30, 2025 | 81.99 Bn |
| Jun 30, 2025 | 80.46 Bn |
| Mar 31, 2025 | 79.62 Bn |
| Sep 30, 2024 | 77.17 Bn |
| Jun 30, 2024 | 74.43 Bn |
| Mar 31, 2024 | 74.40 Bn |
| Dec 31, 2023 | 74.51 Bn |
| Sep 30, 2023 | 74.77 Bn |
| Jun 30, 2023 | 74.49 Bn |
| Mar 31, 2023 | 74.39 Bn |
| Dec 31, 2022 | 73.44 Bn |
| Sep 30, 2022 | 73.52 Bn |
| Jun 30, 2022 | 74.98 Bn |
| Mar 31, 2022 | 75.48 Bn |
| Dec 31, 2021 | 75.43 Bn |
| Sep 30, 2021 | 62.44 Bn |
| Jun 30, 2021 | 62.02 Bn |
| Mar 31, 2021 | 63.94 Bn |
| Dec 31, 2020 | 63.82 Bn |
| Sep 30, 2020 | 63.22 Bn |
| Jun 30, 2020 | 61.27 Bn |
| Mar 31, 2020 | 58.74 Bn |
| Dec 31, 2019 | 56.91 Bn |
| Sep 30, 2019 | 57.19 Bn |
| Jun 30, 2019 | 59.67 Bn |
| Mar 31, 2019 | 57.00 Bn |
| Dec 31, 2018 | 56.76 Bn |
| Sep 30, 2018 | 58.29 Bn |
| Jun 30, 2018 | 60.98 Bn |
| Mar 31, 2018 | 61.96 Bn |
| Dec 31, 2017 | 63.11 Bn |
| Sep 30, 2017 | 63.76 Bn |
| Jun 30, 2017 | 64.64 Bn |
| Mar 31, 2017 | 65.03 Bn |
| Dec 31, 2016 | 64.76 Bn |
| Sep 30, 2016 | 68.90 Bn |
| Jun 30, 2016 | 68.55 Bn |
| Mar 31, 2016 | 69.98 Bn |
| Dec 31, 2015 | 71.93 Bn |
| Sep 30, 2015 | 72.67 Bn |
| Jun 30, 2015 | 74.26 Bn |
| Mar 31, 2015 | 75.42 Bn |
| Dec 31, 2014 | 65.56 Bn |
| Sep 30, 2014 | 67.09 Bn |
| Jun 30, 2014 | 64.27 Bn |
| Mar 31, 2014 | 67.22 Bn |
| Dec 31, 2013 | 69.96 Bn |
| Sep 30, 2013 | 68.65 Bn |
| Jun 30, 2013 | 69.88 Bn |
| Dec 31, 2012 | 71.28 Bn |
| Jun 30, 2012 | 69.89 Bn |
| Mar 31, 2012 | 71.17 Bn |
| Dec 31, 2011 | 71.95 Bn |
| Sep 30, 2011 | 72.43 Bn |
| Jun 30, 2011 | 73.83 Bn |
| Mar 31, 2011 | 74.84 Bn |
| Dec 31, 2010 | 76.72 Bn |
| Sep 30, 2010 | 80.08 Bn |
| Jun 30, 2010 | 79.92 Bn |
| Mar 31, 2010 | 83.35 Bn |
| Dec 31, 2009 | 83.88 Bn |
| Sep 30, 2009 | 17.38 Bn |
| Jun 30, 2009 | 16.87 Bn |